NeuroOne Medical Technologies Set to Join Russell Microcap Index

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on neurological disorders, announced its expected inclusion in the Russell Microcap® Index as part of the first semi-annual 2026 Russell indexes reconstitution. The announcement was made via NEWMEDIAWIRE, with the reconstitution taking effect after the US market close on June 26, 2026. CEO Dave Rosa expressed excitement, stating that the inclusion reflects the company's commercial momentum across its FDA-cleared electrode and ablation technologies, and expects it to expand visibility among institutional investors. FTSE Russell's shift to semi-annual reconstitutions starting in 2026 underscores the dynamic nature of index membership.

NeuroOne markets a portfolio of four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These technologies aim to reduce hospitalizations and surgical procedures while improving outcomes. The company is also researching drug delivery, basivertebral nerve ablation, and spinal cord stimulation. For more details, visit nmtc1.com. The company's inclusion in the Russell Microcap® Index is a key milestone, signaling growing recognition in the investment community and potentially broadening its shareholder base.

NeuroOne's forward-looking statements caution about risks such as supply chain disruptions, regulatory changes, and market acceptance. The company remains focused on transforming neurological disorder treatments, and its index inclusion could attract more institutional interest, supporting its mission. This move aligns with NeuroOne's strategy to leverage its electrode and ablation technologies for both diagnostic and therapeutic functions, potentially lowering healthcare costs and improving patient care.